Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)
China · Delayed Price · Currency is CNY 69.33
+1.52 (2.24%)
At close: Oct 9, 2026
SHE:301520 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 6,431 | 2,633 | 2,567 | 3,687 | - | - | |
Market Cap Growth | 132.54% | 2.57% | -30.38% | - | - | - |
Enterprise Value | 5,437 | 1,473 | 1,425 | 2,483 | - | - |
Last Close Price | 69.33 | 28.14 | 27.02 | 38.37 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 658.89 | 72.26 | 30.01 | 34.11 | - | - |
PS Ratio | 29.90 | 9.60 | 6.77 | 10.79 | - | - |
PB Ratio | 4.21 | 1.74 | 1.70 | 2.52 | - | - |
P/TBV Ratio | 5.09 | 1.75 | 1.71 | 2.54 | - | - |
P/FCF Ratio | - | - | 511.43 | - | - | - |
P/OCF Ratio | - | - | 54.80 | 51.26 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 25.28 | 5.37 | 3.76 | 7.27 | - | - |
EV/EBITDA Ratio | - | 79.58 | 21.38 | 22.03 | - | - |
EV/EBIT Ratio | - | 521.69 | 27.66 | 24.10 | - | - |
EV/FCF Ratio | - | - | 283.99 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.00 | 0.00 | 0.00 | 0 | 0.00 |
Debt / EBITDA Ratio | - | 0.09 | 0.02 | 0.01 | 0.00 | 0.00 |
Debt / FCF Ratio | - | - | 0.32 | - | 0.00 | 0.00 |
Net Debt / Equity Ratio | -0.67 | -0.76 | -0.79 | -0.79 | -0.56 | -0.69 |
Net Debt / EBITDA Ratio | 88.85 | -62.10 | -18.02 | -10.25 | -1.84 | -1.86 |
Net Debt / FCF Ratio | 32.48 | 42.35 | -239.34 | 82.25 | -8.61 | -4.05 |
Asset Turnover | 0.13 | 0.17 | 0.24 | 0.35 | 0.76 | 0.87 |
Inventory Turnover | 149.16 | 143.51 | 174.40 | 314.33 | 414.83 | 358.07 |
Quick Ratio | 4.92 | 20.55 | 18.51 | 19.34 | 4.28 | 4.96 |
Current Ratio | 4.99 | 20.79 | 18.77 | 20.35 | 4.39 | 5.11 |
Return on Equity (ROE) | 0.64% | 2.41% | 5.75% | 12.04% | 34.98% | 42.65% |
Return on Assets (ROA) | -0.99% | 0.11% | 2.05% | 6.61% | 17.44% | 21.44% |
Return on Invested Capital (ROIC) | -6.13% | 0.83% | 15.86% | 41.02% | 78.67% | 140.66% |
Return on Capital Employed (ROCE) | -1.70% | 0.20% | 3.40% | 7.00% | 28.30% | 34.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.15% | 1.38% | 3.33% | 2.93% | - | - |
FCF Yield | -0.49% | -1.03% | 0.20% | -0.38% | - | - |
Dividend Yield | 0.31% | 0.76% | 0.92% | 0.93% | - | - |
Payout Ratio | 206.17% | 63.70% | 36.41% | - | - | - |
Buyback Yield / Dilution | 2.39% | 0.87% | -23.64% | -7.83% | -0.40% | -4.40% |
Total Shareholder Return | 2.70% | 1.63% | -22.71% | -6.90% | -0.40% | -4.40% |